Changes to the Code
S. 2730 · Kidney Care Access Protection Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
42 U.S.C. § 1395w–23 Payments to Medicare+Choice organizations
1 change the bill asks for here, 1 carried out
- Carried out:
Section 1853(c) of the Social Security Act (42 U.S.C. 1395w–23(c)) is amended by adding at the end the following new paragraph:
(8) Treatment of innovative products for enrollees with end-stage renal disease.— (A) In general.— Beginning January 1, 2026, the Secretary shall make direct payment adjustments to providers of services or renal dialysis facilities for— (i) any new renal dialysis drug or …
§ 1395w–23(c)–(d)
Start of § 1395w–23 to (c)(6)(B)(vi) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (c)(6)(C) | (C) Adjustment for over or under projection of national per capita Medicare+Choice growth percentage | (C) Adjustment for over or under projection of national per capita Medicare+Choice growth percentage | ||
| Beginning with rates calculated for 1999, before computing rates for a year as described in paragraph (1), the Secretary shall adjust all area-specific and national Medicare+Choice capitation rates (and beginning in 2000, the minimum amount) for the previous year for the differences between the projections of the national per capita Medicare+Choice growth percentage for that year and previous years and the current estimate of such percentage for such years, except that for purposes of paragraph (1)(C)(v)(II), no such adjustment shall be made for a year before 2004. | Beginning with rates calculated for 1999, before computing rates for a year as described in paragraph (1), the Secretary shall adjust all area-specific and national Medicare+Choice capitation rates (and beginning in 2000, the minimum amount) for the previous year for the differences between the projections of the national per capita Medicare+Choice growth percentage for that year and previous years and the current estimate of such percentage for such years, except that for purposes of paragraph (1)(C)(v)(II), no such adjustment shall be made for a year before 2004. | |||
| (c)(7) | (7) Adjustment for national coverage determinations and legislative changes in benefits | (7) Adjustment for national coverage determinations and legislative changes in benefits | ||
| If the Secretary makes a determination with respect to coverage under this subchapter or there is a change in benefits required to be provided under this part that the Secretary projects will result in a significant increase in the costs to Medicare+Choice of providing benefits under contracts under this part (for periods after any period described in section 1395w–22(a)(5) of this title), the Secretary shall adjust appropriately the payments to such organizations under this part. Such projection and adjustment shall be based on an analysis by the Chief Actuary of the Centers for Medicare & Medicaid Services of the actuarial costs associated with the new benefits. | If the Secretary makes a determination with respect to coverage under this subchapter or there is a change in benefits required to be provided under this part that the Secretary projects will result in a significant increase in the costs to Medicare+Choice of providing benefits under contracts under this part (for periods after any period described in section 1395w–22(a)(5) of this title), the Secretary shall adjust appropriately the payments to such organizations under this part. Such projection and adjustment shall be based on an analysis by the Chief Actuary of the Centers for Medicare & Medicaid Services of the actuarial costs associated with the new benefits. | |||
| (c)(8) | (8) [inserted: Treatment of innovative products for enrollees with end-stage renal disease.—] | |||
| (c)(8)(A) | (A) [inserted: In general.—] | |||
| [inserted: Beginning January 1, 2026, the Secretary shall make direct payment adjustments to providers of services or renal dialysis facilities for—] | ||||
| (c)(8)(A)(i) | (i) [inserted: ] | |||
| [inserted: any new renal dialysis drug or biological product that receives a transitional drug add-on payment adjustment under section 413.234(c) of title 42, Code of Federal Regulations; or] | ||||
| (c)(8)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: an item or service that receives a transitional add-on payment adjustment for new and innovative equipment and supplies under section 413.236 of such title.] | ||||
| (c)(8)(B) | (B) [inserted: Amount of direct payment.—] | |||
| [inserted: The amount of the adjustment shall equal the amount determined under the end-stage renal disease prospective payment system described in section 1881(b)(14).] | ||||
| (c)(8)(C) | (C) [inserted: Duration of direct payment.—] | |||
| [inserted: The Secretary shall make payments under subparagraph (A) for the duration of the transitional payment under the end-stage renal disease prospective payment system described in such section.] | ||||
| (d) | (d) MA payment area; MA local area; MA region defined | (d) MA payment area; MA local area; MA region defined | ||
| (d)(1) | (1) MA payment area | (1) MA payment area | ||
| In this part, except as provided in this subsection, the term “MA payment area” means— | In this part, except as provided in this subsection, the term “MA payment area” means— | |||
Rest of § 1395w–23 unchanged
42 U.S.C. § 1395rr End stage renal disease program
11 changes the bill asks for here, 7 carried out
- Carried out:
Section 1881(b)(14) of the Social Security Act (42 U.S.C. 1395rr(b)(14)) is amended by adding at the end the following new subparagraph:
(J) Payment for new and innovative drugs, biologicals, and devices that are renal dialysis services.— (i) In general.— For any new renal dialysis drug or biological product that is used to treat or manage a condition as defined in section 413.234(a) of title 42, Code of Federal …
- Carried out:
by redesignating clauses (i) through (iv) as subclauses (I) through (IV), respectively;
- Carried out:
by inserting
(i)
after(B)
; - Not carried out:
in clause (i)(IV), as added by paragraph (2), by striking
clause (i)
and insertingsubclause (I)
;The bill points to clause (i) of § 1395rr(b)(14)(B), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no clause (i) in /us/usc/t42/s1395rr/b/14/B - Not carried out:
in the flush text at the end, by striking Such term does not and inserting the following:
(ii) Such term— (I) does not;
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: in the flush text at the end, by striking QTEXT and inserting the following: QCONTENT; - Not carried out:
in subclause (I), by striking the period at the end and inserting
; and
; andThe bill points to clause (ii) of § 1395rr(b)(14)(B), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no clause (ii) in /us/usc/t42/s1395rr/b/14/B - Not carried out:
by adding at the end the following:
(II) does not include drugs or biological products used to treat a comorbid disease or condition (including cardiovascular disease, an inflammatory condition, cancer, diabetes, and obesity) that may occur in an individual who has been determined to have end-stage renal diseases …
The bill points to clause (ii) of § 1395rr(b)(14)(B), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no clause (ii) in /us/usc/t42/s1395rr/b/14/B - Carried out:
by adding at the end the following new clause:
(iii) Implementation.— Beginning on the date of enactment of this clause, for purposes of implementing clause (ii)(II), the Secretary shall require that a claim for a drug or biological product described in such clause, that is payable under this part and is furnished by a …
- Carried out:
in subclause (I), by striking
subclauses (II) and (III)
and insertingsubclauses (II), (III), and (IV)
; - Carried out:
in subclause (II), by inserting
and after application of subclause (IV)
aftersubclause (I)
; and - Carried out:
by adding at the end the following new subclause:
(IV) Beginning with 2026, the Secretary shall compute an adjustment to the increase factor described in subclause (I) for the annual update of the payment amounts established under this paragraph for the previous year to account for forecast error (referred to in this subclause …
§ 1395rr(b)(14)(A)–(C)
Start of § 1395rr to (b)(14)(A)(i) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (A)(ii) | (ii) | (ii) | ||
| In implementing the system under this paragraph the Secretary shall ensure that the estimated total amount of payments under this subchapter for 2011 for renal dialysis services shall equal 98 percent of the estimated total amount of payments for renal dialysis services, including payments under paragraph (12)(B)(ii), that would have been made under this subchapter with respect to services furnished in 2011 if such system had not been implemented. In making the estimation under subclause (I), the Secretary shall use per patient utilization data from 2007, 2008, or 2009, whichever has the lowest per patient utilization. | In implementing the system under this paragraph the Secretary shall ensure that the estimated total amount of payments under this subchapter for 2011 for renal dialysis services shall equal 98 percent of the estimated total amount of payments for renal dialysis services, including payments under paragraph (12)(B)(ii), that would have been made under this subchapter with respect to services furnished in 2011 if such system had not been implemented. In making the estimation under subclause (I), the Secretary shall use per patient utilization data from 2007, 2008, or 2009, whichever has the lowest per patient utilization. | |||
| (B) | (B) | (B) | ||
| For purposes of this paragraph, the term “renal dialysis services” includes— | [inserted: (i) ]For purposes of this paragraph, the term “renal dialysis services” includes— | |||
| (B)(I) | [inserted: (I)] | |||
| items and services included in the composite rate for renal dialysis services as of December 31, 2010; | items and services included in the composite rate for renal dialysis services as of December 31, 2010; | |||
| (B)(II) | [inserted: (II)] | |||
| erythropoiesis stimulating agents and any oral form of such agents that are furnished to individuals for the treatment of end stage renal disease; | erythropoiesis stimulating agents and any oral form of such agents that are furnished to individuals for the treatment of end stage renal disease; | |||
| (B)(III) | [inserted: (III)] | |||
| other drugs and biologicals that are furnished to individuals for the treatment of end stage renal disease and for which payment was (before the application of this paragraph) made separately under this subchapter, and any oral equivalent form of such drug or biological; and | other drugs and biologicals that are furnished to individuals for the treatment of end stage renal disease and for which payment was (before the application of this paragraph) made separately under this subchapter, and any oral equivalent form of such drug or biological; and | |||
| (B)(IV) | [inserted: (IV)] | |||
| diagnostic laboratory tests and other items and services not described in clause (i) that are furnished to individuals for the treatment of end stage renal disease. | diagnostic laboratory tests and other items and services not described in clause (i) that are furnished to individuals for the treatment of end stage renal disease. | |||
| (B)(iii) | (iii) [inserted: Implementation.—] | |||
| [inserted: Beginning on the date of enactment of this clause, for purposes of implementing clause (ii)(II), the Secretary shall require that a claim for a drug or biological product described in such clause, that is payable under this part and is furnished by a provider of services or renal dialysis facility, contain the AY modifier (or a successor modifier).] | ||||
| (B) | Such term does not include vaccines. | Such term does not include vaccines. | ||
| (C) | (C) | (C) | ||
| The system under this paragraph may provide for payment on the basis of services furnished during a week or month or such other appropriate unit of payment as the Secretary specifies. | The system under this paragraph may provide for payment on the basis of services furnished during a week or month or such other appropriate unit of payment as the Secretary specifies. | |||
§ 1395rr(b)(14)(F)(i)–(ii)
(b)(14)(D)–(E) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (F) | (F) | (F) | ||
| (i) | (i) | (i) | ||
| (i)(I) | (I) | (I) | ||
| Subject to subclauses (II) and ( | Subject to subclauses (II)[inserted: ,] [inserted: (III), ]and ([inserted: IV]) and clause (ii), beginning in 2012, the Secretary shall annually increase payment amounts established under this paragraph by an ESRD market basket percentage increase factor for a bundled payment system for renal dialysis services that reflects changes over time in the prices of an appropriate mix of goods and services included in renal dialysis services. In order to accomplish the purposes of subparagraph (I) with respect to 2016, 2017, and 2018, after determining the increase factor described in the preceding sentence for each of 2016, 2017, and 2018, the Secretary shall reduce such increase factor by 1.25 percentage points for each of 2016 and 2017 and by 1 percentage point for 2018. | |||
| (i)(II) | (II) | (II) | ||
| Subject to subclause (III), for 2012 and each subsequent year, after determining the increase factor described in subclause (I), the Secretary shall reduce such increase factor by the productivity adjustment described in section 1395ww(b)(3)(B)(xi)(II) of this title. The application of the preceding sentence may result in such increase factor being less than 0.0 for a year, and may result in payment rates under the payment system under this paragraph for a year being less than such payment rates for the preceding year. | Subject to subclause (III), for 2012 and each subsequent year, after determining the increase factor described in subclause (I)[inserted: and after application of subclause (IV)], the Secretary shall reduce such increase factor by the productivity adjustment described in section 1395ww(b)(3)(B)(xi)(II) of this title. The application of the preceding sentence may result in such increase factor being less than 0.0 for a year, and may result in payment rates under the payment system under this paragraph for a year being less than such payment rates for the preceding year. | |||
| (i)(III) | (III) | (III) | ||
| Notwithstanding subclauses (I) and (II), in order to accomplish the purposes of subparagraph (I) with respect to 2015, the increase factor described in subclause (I) for 2015 shall be 0.0 percent pursuant to the regulation issued by the Secretary on December 2, 2013, entitled “Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule” (78 Fed. Reg. 72156). | Notwithstanding subclauses (I) and (II), in order to accomplish the purposes of subparagraph (I) with respect to 2015, the increase factor described in subclause (I) for 2015 shall be 0.0 percent pursuant to the regulation issued by the Secretary on December 2, 2013, entitled “Medicare Program; End-Stage Renal Disease Prospective Payment System, Quality Incentive Program, and Durable Medical Equipment, Prosthetics, Orthotics, and Supplies; Final Rule” (78 Fed. Reg. 72156). | |||
| (i)(IV) | (IV) [inserted: ] | |||
| [inserted: Beginning with 2026, the Secretary shall compute an adjustment to the increase factor described in subclause (I) for the annual update of the payment amounts established under this paragraph for the previous year to account for forecast error (referred to in this subclause as the “forecast error adjustment”). The initial adjustment (in 2026) to the increase factor shall take into account the cumulative forecast error for 2021 and 2022. Subsequent adjustments in succeeding years shall take into account the forecast error from the most recently available year for which there is final data. The forecast error adjustment under this subclause shall apply whenever the difference between the forecasted and actual percentage change in the prices of an appropriate mix of goods and services included in renal dialysis services exceeds 0.5 percentage points.] | ||||
| (ii) | (ii) | (ii) | ||
| For years during which a phase-in of the payment system pursuant to subparagraph (E) is applicable, the following rules shall apply to the portion of the payment under the system that is based on the payment of the composite rate that would otherwise apply if the system under this paragraph had not been enacted: | For years during which a phase-in of the payment system pursuant to subparagraph (E) is applicable, the following rules shall apply to the portion of the payment under the system that is based on the payment of the composite rate that would otherwise apply if the system under this paragraph had not been enacted: | |||
| (ii)(I) | (I) | (I) | ||
| The update under clause (i) shall not apply. | The update under clause (i) shall not apply. | |||
§ 1395rr(b)–(c)
(b)(14)(F)(ii)(II)–(H)(i) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(14)(H)(ii) | (ii) | (ii) | ||
| included in subparagraph (B) for purposes of payment under this paragraph. | included in subparagraph (B) for purposes of payment under this paragraph. | |||
| (b)(14)(I) | (I) | (I) | ||
| For services furnished on or after January 1, 2014, and before January 1, 2015, the Secretary shall, by comparing per patient utilization data from 2007 with such data from 2012, make reductions to the single payment that would otherwise apply under this paragraph for renal dialysis services to reflect the Secretary’s estimate of the change in the utilization of drugs and biologicals described in clauses (ii), (iii), and (iv) of subparagraph (B) (other than oral-only ESRD-related drugs, as such term is used in the final rule promulgated by the Secretary in the Federal Register on August 12, 2010 (75 Fed. Reg. 49030)). In making reductions under the preceding sentence, the Secretary shall take into account the most recently available data on average sales prices and changes in prices for drugs and biological2 reflected in the ESRD market basket percentage increase factor under subparagraph (F). | For services furnished on or after January 1, 2014, and before January 1, 2015, the Secretary shall, by comparing per patient utilization data from 2007 with such data from 2012, make reductions to the single payment that would otherwise apply under this paragraph for renal dialysis services to reflect the Secretary’s estimate of the change in the utilization of drugs and biologicals described in clauses (ii), (iii), and (iv) of subparagraph (B) (other than oral-only ESRD-related drugs, as such term is used in the final rule promulgated by the Secretary in the Federal Register on August 12, 2010 (75 Fed. Reg. 49030)). In making reductions under the preceding sentence, the Secretary shall take into account the most recently available data on average sales prices and changes in prices for drugs and biological2 reflected in the ESRD market basket percentage increase factor under subparagraph (F). | |||
| (b)(14)(J) | (J) [inserted: Payment for new and innovative drugs, biologicals, and devices that are renal dialysis services.—] | |||
| (b)(14)(J)(i) | (i) [inserted: In general.—] | |||
| [inserted: For any new renal dialysis drug or biological product that is used to treat or manage a condition as defined in section 413.234(a) of title 42, Code of Federal Regulations that received a transitional drug add-on payment adjustment (referred to in this subparagraph as “TDAPA”) under section 413.234(c) of such title, and was furnished on or after January 1, 2024, the Secretary shall establish a permanent add-on adjustment to the base rate for claims submitted on or after January 1, 2026, that includes the administration of such drugs or biologicals.] | ||||
| (b)(14)(J)(ii) | (ii) [inserted: Calculation of the post-TDAPA add-on adjustment.—] | |||
| [inserted: In calculating the add-on adjustment described in clause (i), the Secretary shall—] | ||||
| (b)(14)(J)(ii)(I) | (I) [inserted: ] | |||
| [inserted: base the calculation on—] | ||||
| (b)(14)(J)(ii)(I)(aa) | (aa) [inserted: ] | |||
| [inserted: except as provided in items (bb) and (cc), the most recent 12-month period of utilization for the new renal dialysis drug or biological product and the most recent available full calendar quarter of average sales price data for such drug or product;] | ||||
| (b)(14)(J)(ii)(I)(bb) | (bb) [inserted: ] | |||
| [inserted: if the most recent available full calendar quarter of average sales price data reflects 0 or negative sales, 100 percent of the wholesale acquisition cost (as defined in section 1847A(c)(6)) of such drug or product; or] | ||||
| (b)(14)(J)(ii)(I)(cc) | (cc) [inserted: ] | |||
| [inserted: if the wholesale acquisition cost is not available, the drug manufacturer’s invoice;] | ||||
| (b)(14)(J)(ii)(II) | (II) [inserted: ] | |||
| [inserted: calculate the post-TDAPA add-on payment adjustment as the expenditures for the new renal dialysis drug or biological product divided by the total number of renal dialysis services during which such drug or biological was administered during the same period;] | ||||
| (b)(14)(J)(ii)(III) | (III) [inserted: ] | |||
| [inserted: set the amount of the add-on adjustment as an amount equal to 65 percent of the amount calculated under subclause (II);] | ||||
| (b)(14)(J)(ii)(IV) | (IV) [inserted: ] | |||
| [inserted: update the add-on adjustment annually to account for inflationary changes; and] | ||||
| (b)(14)(J)(ii)(V) | (V) [inserted: ] | |||
| [inserted: apply the add-on adjustment amount immediately upon the expiration of the TDAPA period and availability of the post-TDAPA add-on adjustment.] | ||||
| (b)(14)(J)(iii) | (iii) [inserted: Implementation.—] | |||
| [inserted: This subparagraph shall not be implemented in a budget neutral manner and shall not be adjusted by any applicable patient-level case-mix adjustments described in section 413.235 of title 42, Code of Federal Regulations (or any successor regulation).] | ||||
| (c) | (c) Renal disease network areas; coordinating councils, executive committees, and medical review boards; national end stage renal disease medical information system; functions of network organizations | (c) Renal disease network areas; coordinating councils, executive committees, and medical review boards; national end stage renal disease medical information system; functions of network organizations | ||
| (c)(1) | (1) | (1) | ||
| (c)(1)(A) | (A) | (A) | ||
Rest of § 1395rr unchanged
42 U.S.C. § 1395w–21 Eligibility, election, and enrollment
The bill's words for this section
- Not carried out:
in paragraph (1), by inserting
1853(c)(8),
after1886(h)(3)(D),
; and“1886(h)(3)(D),” isn't in § 1395w–21(i)(1) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“1886(h)(3)(D),” not found in /us/usc/t42/s1395w–21/i/1 - Not carried out:
in paragraph (2), by inserting
1853(c)(8),
after1853(h),
.“1853(h),” isn't in § 1395w–21(i)(2) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“1853(h),” not found in /us/usc/t42/s1395w–21/i/2